XM does not provide services to residents of the United States of America.

Japan's Nikkei rebounds in broad-based buying after Wall Street comeback



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>Japan's Nikkei rebounds in broad-based buying after Wall Street comeback</title></head><body>

By Brigid Riley

TOKYO, July 29 (Reuters) -Japan's Nikkei share average rebounded on Monday from a three-month low hit in the previous session, after Wall Street closed higher at the end of last week on a benign inflation report.

The Nikkei .N225 rose 1.99% to 38,415.75 by the midday break in a broad-based rally, while the broader Topix .TOPX was up 1.88% at 2,750.28.

The Nikkei fell for an eighth straight session on Friday, hitting its weakest level since late April amid a surge in the yen and declines in U.S. technology stocks.

Wall Street's major indexes ended higher on Friday as investors flocked back to tech megacaps that had triggered broad sell-offs earlier in the week, and U.S. inflation data boosted optimism that the Federal Reserve will soon commence cutting interest rates. .N

"The decline in U.S. technology shares has finally paused... so that seems to be working as a positive factor" for Japanese equities, said Masahiro Ichikawa, chief market strategist at Sumitomo Mitsui DS Asset Management.

Investors snapped up shares on the dip, with all but 10 shares of the Nikkei's 225 constituents advancing.

Big names surged to give the overall index a hefty lift. Chip-related shares Tokyo Electron 8035.T and Advantest 6857.T were up 2.7% and 3.4%, respectively.

AI-focused startup investor SoftBank Group 9984.T climbed nearly 3%, and Uniqlo parent Fast Retailing 9983.T rose 1.4%.

All 33 of the Tokyo Stock Exchange's industry sectors gained.

The rally comes ahead of the Bank of Japan and the Fed's policy meetings on July 30-31, and earnings from more of the United States' so-called Magnificent Seven.

Among individual stocks, Shin-Etsu Chemical 4063.T surged 6.8% after the silicon wafer maker beat its operating profit forecast for the April-June period.

Eisai 4523.T tumbled 12% to hit the bottom of the pack, after the European Union regulator rejected the drugmaker's Leqembi treatment for early Alzheimer's disease.



Reporting by Brigid Riley; Editing by Subhranshu Sahu

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.